EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
13 hours ago · “If approved, this Sarclisa-based combination could establish a new standard-of-care treatment approach for patients in the EU, helping to address a critical care gap in multiple myeloma ...
Isatuximab Plus VRd Earns CHMP Recommendation for Newly …
6 hours ago · Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma. News release. Sanofi. November 15, 2024.
Press Release: Sarclisa recommended for EU approval by the
1 day ago · If approved, this Sarclisa-based combination could establish a new standard-of-care treatment approach for patients in the EU, helping to address a critical care gap in multiple myeloma treatment ...
FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
Sep 20, 2024 · The IMROZ trial showed that when Sarclisa is added to Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd) in newly diagnosed multiple myeloma (NDMM) patients who are not eligible for autologous stem cell transplant (ASCT), these patients experienced longer progression-free survival (PFS) compared to those who received VRd-alone.
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
Jun 3, 2024 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
Sep 20, 2024 · The US Food and Drug Administration (FDA) has approved SARCLISA (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
Sanofi Induction Therapy Improves PFS | Int'l Myeloma Fndtn
According to an August 8, 2024, Sanofi press release, "Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant."
Press Room - Sanofi US News
Aug 8, 2024 · Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant.
Sanofi wins US approval for multiple myeloma drug in newly …
Sep 20, 2024 · The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed ...
Press Release: Sarclisa recommended for EU approval by the
1 day ago · If approved, this Sarclisa-based combination could establish a new standard-of-care treatment approach for patients in the EU, helping to address a critical care gap in multiple myeloma treatment ...
- Some results have been removed